Risk of hepatitis B virus reactivation in patients treated with ibrutinib

Blood. 2018 Apr 26;131(17):1987-1989. doi: 10.1182/blood-2018-01-826495. Epub 2018 Feb 28.

Authors

Sarah P Hammond^{1

2}, Kaiwen Chen^{1

2}, Alisha Pandit^{1

2}, Matthew S Davids², Nicolas C Issa^{1

2}, Francisco M Marty^{1

2}

Affiliations

¹ Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA; and.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

PMID: 29490923
DOI: 10.1182/blood-2018-01-826495

No abstract available

Publication types

Clinical Trial
Letter
Multicenter Study

MeSH terms

Adenine / analogs & derivatives
Aged
Aged, 80 and over
Female
Follow-Up Studies
Hematologic Neoplasms* / drug therapy
Hematologic Neoplasms* / epidemiology
Hematologic Neoplasms* / pathology
Hematologic Neoplasms* / virology
Hepatitis B virus / physiology*
Hepatitis B* / chemically induced
Hepatitis B* / epidemiology
Hepatitis B* / pathology
Humans
Male
Middle Aged
Piperidines
Pyrazoles / administration & dosage
Pyrazoles / adverse effects*
Pyrimidines / administration & dosage
Pyrimidines / adverse effects*
Virus Activation / drug effects*

Substances

Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Adenine